Exelixis (EXEL) Other financing activities (2010 - 2026)
Exelixis' (EXEL) quarterly Other financing activities came in at $7.5 million in Q2 2026, down 35.74% year-on-year from $11.6 million in Q2 2025, and down 5.12% quarter-over-quarter from $7.9 million in Q1 2026.
Exelixis (EXEL) Other financing activities (2010 - 2026) Analysis & Trends
Exelixis' Other financing activities history runs 17 years deep, the most recent figure standing at $7.5 million for Q2 2026.
- On a quarterly basis, Other financing activities fell 35.74% year-over-year to $7.5 million in Q2 2026; TTM through Apr 2026 was $45.0 million, a 30.97% decrease from a year earlier, with the FY2026 full-year figure at $49.1 million, down 20.55% from the prior year.
- Other financing activities slipped to $7.5 million in Q2 2026 per EXEL's latest filing, from $7.9 million in the prior quarter.
- Across five years, Other financing activities topped out at $26.1 million in Q3 2025 and bottomed at $2.9 million in Q3 2022.
- The 5-year median for Other financing activities is $8.3 million (2024), against an average of $10.3 million.
- Across the five-year window, Other financing activities jumped 186.09% in 2024 and tumbled 82.05% in 2025, its largest moves.
- Year by year, Other financing activities stood at $5.2 million in 2022, then soared by 74.97% to $9.1 million in 2023, then soared by 117.25% to $19.8 million in 2024, then tumbled by 82.05% to $3.6 million in 2025, then soared by 110.36% to $7.5 million in 2026.
- Per Business Quant, the three latest EXEL Other financing activities figures stand at $7.5 million (Q2 2026), $7.9 million (Q1 2026), and $3.6 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Exelixis | 14.50 Bn | 13.72 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 7.47 Mn |
| Apr 3, 2026 | 7.47 Mn |
| Jan 2, 2026 | 7.88 Mn |
| Jan 2, 2026 | 7.88 Mn |
| Oct 3, 2025 | 3.55 Mn |
| Oct 3, 2025 | 3.55 Mn |
| Jul 4, 2025 | 26.08 Mn |
| Jul 4, 2025 | 26.08 Mn |
| Apr 4, 2025 | 11.63 Mn |
| Apr 4, 2025 | 11.63 Mn |
| Jan 3, 2025 | 18.82 Mn |
| Jan 3, 2025 | 18.82 Mn |
| Sep 27, 2024 | 19.79 Mn |
| Sep 27, 2024 | 19.79 Mn |
| Jun 28, 2024 | 14.92 Mn |
| Jun 28, 2024 | 14.92 Mn |
| Mar 29, 2024 | 8.32 Mn |
| Mar 29, 2024 | 8.32 Mn |
| Dec 29, 2023 | 9.11 Mn |
| Dec 29, 2023 | 9.11 Mn |